drugset / Trial / NCT06329206
A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors
Phase 1
Recruiting
156 enrolled
Suzhou Genhouse Bio Co., Ltd.
Henan Cancer Hospital · collabHubei Cancer Hospital · collabThe First Affiliated Hospital of Zhengzhou University · collabZhejiang Cancer Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase Ia/Ib, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, pharmacodynamics (PD) and preliminary efficacy of GH2616 Tablet in subjects with advanced solid tumors. It includes two parts: the dose escalation study (Phase Ia) and the dose expansion study (Phase Ib).
Timeline
- Start
- 2024-03-20
- Primary completion
- 2026-04-25
- Completion
- 2026-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GH2616 Tablets | Unknown | — | Oral |